SPECIFICATION 4-phenylphthalazine derivativesThis invention relates to a 4-phenylphthalazine derivative represented by the following formula [I] or a pharmaceutically acceptable salt thereof:
wherein X stands for NH or O; R' an alkyl group having 1 to 5 carbon atoms, an alkoxy grouphaving 1 to 5 carbon atoms, a halogen atom, an alkoxycarbonyl group having 2 to 6 total carbonatoms, a carboxyl group, a cyano group, an alkylcarbonyl group having 2 to 4 total carbon atoms, ahydroxyl group or a trifluoromethyl group;R2 and R3, which may be identical or different (may alsobe the same as or different from R1), each represent an alkyl group having 1 to 5 carbon atoms, analkoxy group having 1 to 5 carbon atoms, a halogen atom, an alkoxycarbonyl group having 2 to 6total carbon atoms, a carboxyl group, an alkylcarbonyl group having 2 to 4 total carbon atoms, ahydroxyl group or a trifluoromethyl group; and each of I, m and n is an integer of zero to 3(provided that 1=1 to 3 and m=n=zero when X is 0, and the case where l=m=n=zero is excludedwhen X is NH), each plural number of R', R2 and R3 being identical or different when the integers I, m and n are two or more, and also to. a process for producing the same.
As 4-phenylphthalazine derivatives analogous to those of the present invention, there have heretofore been known 1 -anilino-4-phenylphthalazine (Ber., 38, 3923  (1905)], 1 -phenoxy-4- phenylphthalazine [Journal of Pharmacology, 88, 83 (1968], l-[2-(2-methylallyl)-phenoxy]-4- phenylphthalazine, 1 -(2-allylphenoxy)-4-phenylphthalazine [Chem. Pharm. Bull., 24, 1581-1595 (1976)]. These compounds are disclosed merely as intermediates and there is nothing done about uses thereof.The compounds I -[2-(2-methylallyl)phenoxyj-4-phenylphthalazine and 1 -(2-allylphenoxy)-4- phenylphthalazine are iiable to undergo ring-closure reaction or other undesirable reactions due to the presence of double bonds in the substituents, whereby structural changes are caused.
On the other hand, studies have been made about 1 -alkylamino-4-phenylphthalazine derivatives, 1-alkoxy-4-phenylphthalazine derivative [J. Med.Chem.  '2,555(1969)] and 1-(piperazine-1-yl)-4phenylphthalazine derivative (Japanese Patent Publication 39944/1973) for their uses as antiinflammatory agents. However, there is no description about 1-anilino derivatives and 1 -phenoxy derivatives.
The present inventors have successfully synthesized the novel compounds represented by the above formula [I] which have not been described in literatures. They have further progressed their studies to find out that these compunds have potent inhibitory activity against platelet aggregation.
Thus, the compounds of the present invention are considered to be applicable for prevention or therapy of the diseases induced by increased platelet aggregation ability such as cerebral thrombosis, cerebral infarction, myocardial infarction and arteriosclerotic diseases. It is therefore the primary object of the present invention to provide a novel compound represented by the formula 111 having a potent inhibitory activity against platelet aggregation.
The compound according to the present invention is represented by the following formula [I]:
wherein all the symbols have the same meanings as defined above.
In the above formula [I], the alkyl group as represented by R', R2 and R3 may be exemplified by methyl, ethyl, propyl, iso-propyl, n-butyl, t-butyl and amyl. Typical examples of the alkoxy group are methoxy, ethoxy, propoxy, butoxy and amyloxy. As a halogen atom, there may be mentioned fluorine, chlorine, bromine and iodine. The alkoxycarbonyl group may include, for example, methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, amyloxycarbonyl, etc. As the alkylcarbonyl group there may be used acetyl, propionyl, butylyl or others.
In the compounds of the present invention, R' may preferably be an alkyl group, an alkoxy group, a halogen atom or a trifluoromethyl group. On the other hand, R2 may preferably be an alkyl group, an alkoxy group or a halogen atom, while R3 an alkyl group.
In the above formula [I], each of the integers represented by I, m and n may be variable from zero to 3. But there are some restrictions depending on the species of X. When X represents 0 (an oxygen atom), both m and n are required to be zero, while I may be variable from 1 to 3. On the other hand, when X represents NH group, the case where all of the integers are zero is excluded; in other words, there is at least one substituent on the aromatic nuclei. Thus, when X is NH, there are so many possible combinations in number of the substituents on the aromatic nuclei. Among them, the following four combinations are found to be particularly preferred:(1) I=1 to 3, m=n=zero;(2) 1=1 to 2, m=1 to 2, n=zero;(3) 1=1 to 2, m=zero, n=1 to 2; and(4)- I=m=zero, n=1 to 2.
Also, when X is 0, I is preferred to be 1 or 2, while m=n=O.
The compound represented by the formula [I] can also form a pharmaceutically acceptable salt through the reaction of the basic nitrogen thereof with an acid. For example, there may be mentioned salts with mineral acids such as hydrogen chloride, sulfuric acid, hydrobrobromic acid, phosphoric acid, etc. or methanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, acetic acid, glycolic acid, glucuronic acid, maleic acid, oxalic acid, ascorbic acid, citric acid, salicylic acid, and so on.
In the following, there are enumerated concrete examples of the compounds represented by the formula [I].
Compound No. Name of Compound (1) 1 -(4-Methylanilino)-4-phenylphthalazine (2) 1 (3-Methylanilino)-4-phenylphthalazine (3) 1-(2-Methylanilino)-4-phenylphthalazine (4) 1 -(4-Ethylanilino)-4-phenylphthalazine (5) 1-(2-Ethylanilino)-4-phenylphthalazine (6) 1 -(4-n-Butylani lino)-4-phenylphthalazine (7) 1-(3-n-Butylanilino)-4-phenylphthalazine (8) 1-(4-t-Butylanilino)-4-phenylphthalazine (9) 1-(4-Methoxyanilino)-4-phenylphthalazine (10) 1 -(3-Methoxyanilino)-4-phenylphthalazine (11) 1 -(3-Propoxyanilino)-4-phenylphthalazine (12) 1 -(4-n-Butoxyanilino)-4-phenylphthalazine (13) 1 -(4-Fluoroanilino)-4-phenylphthalazine (14) 1 -(3-Fluoroanilino)-4-phenylphthalazine (15) 1 -(2-Fluoroanilino)-4-phenylphthalazine (16) 1 -(4-Chloroanilino)-4-phenylphthalazine (17) 1  -(3-Chloroanilino)-4-phenylphthalazine (18) 1 -(2-Chloroanilino)-4-phenylphthalazine (19) 1 -(4-Bromoanilino)-4-phenylphthalazine (20) 1-(3-Bromoanilino)-4-phenylphthalazine (21) 1 -4-lodoanilino)-4-phenylphthalazine (22) 1-(3-lodoanilino)-4-phenylphthalazine (23) 1 -(4-Ethoxycarbonylanilino)-4-phenylphthalazine (24) 1-(4-Carboxylanilino)-4-phenylphthalazine (25) 1 -(4-Cyanoanilino)-4-phenylphthalazine (26) 1-(4-Acetylanilino)-4-phenylphthalazine (27) 1 -(4-Tdfluoromethylanilino)-4-phenylphthalazine (28) 1 -(3-Trifluoromethylanilino)-4-phenylphthalazine (29) 1-(2-Trifluoromethylanilino)-4-phenylphthalazine (30) 1   -(3-Hydroxylanilino)-4-phenylphthalazine  Compound No. Name of Compound (31) 1 -(2,3-Dimethylanilino)-4-phenylphthalazine (32) 1-(2,4-Dimethylanilino)-4-phenylphthalazine (33) 1-(2,50Dimethylanilino)-4-phenylphthalazine (34) 1-(3,4-Dimethylanilino)-4-phenylphthalazine (35) 1-(2,5-Diethylanilino)-4-phenylphthalazine (36) 1-(2,5-Dipropylanilino)-4-phenylphthalazine (37) 1 -(2,5-Dimethoxyanilino)-4-phenylphthalazine (38) 1-(3,4-Dimethoxyanilino)-4-phenylphthalazine (39) 1-(2,5-Dichloroanilino)-4-phenylphthalazine (40) 1 -(3,4-Dichloroanilino)-4-phenylphthalazine (41) 1-(2,5-Difluoroanilino)-4-phenylphthalazine (42) 1  -(3-Chloro-4-methylanilino)-4phenylphthalazine (43) 1-(2-Methyl-3-chloroanilino)-4-phenylphthalazine (44) 1-(2-Methyl-4-chloroanilino)-4-phenylphthalazine (45) 1 -(3-Methyl-4-chlorani lino)-4-phenylphthalazine (46) 1 -(3-Fluoro-4-methylanilino)-4-phenylphthalazine (47) 1-(2-lVlethoxy-5-methylanilino)-4-phenylphthalazine (48) 1 -(5-Chloro-2-methoxyanilino)-4-phenylphthalazine (49) 1-(2-Methyl-5-trifluoromethylanilino)-4-phenylphthalazine(50) 1-(2-Methoxy-5-trifluoromethylanilino)-4-phenylphthalazine (51) 1 -(2,4,6-Trimethylanilino)-4-phenylphthalazine (52) 1-(3,4,5-Trimethoxyanilino)-4-phenylphthalazine (53) 1 -Anilino-4-(4-methyl phenyl)phthalazine(54) 1-(4-Methylanilino)-4-(4-methylphenyl)phthalazine(55) 1  -(4-Butylanilino)-4-(4-methylphenyl)phthalazine(56) 1-(2,5-Dimethylanilino)-4-(4-methylphenyl)phthalazine(57) 1 -(3-Methoxyanilino)-4-(4-methylphenyl)phthalazine (58) 1 -(4-Butoxya nilino)-4-(4-methylphenyl)phthalazine (59) 1 -(2,5-Dimethoxyanilino)-4-(4-methylphenyl)phthalazine (60) 1-(3-Chloroaniiino)-4-(4-methylphenyl)phthalazine (61) 1-(3-Bromoanilino)-4-(4-methylphenyl)phthalazine(62) 1 -(3-Fluoroanilino)-4-(4-methylphenyl)phthalazine (63) 4-(4-Methylphenyl)-1 -(3-trifluoromethylaniliono)phthalazine(64) 1 -(5-Chloro-2-methoxyanilino)-4-(4-methyl phenyl)phthalazine (65) 1-(3-Chloro-4-methylanilino)-4-(4-methylphenyl)phthalazine (66) 1 -(4-Ethoxywarbonylani  lino)-4-(4-methylphenyl)phthalazine (67) 1-Anilino-4-(4-butylphenyl) phthanlazine (68) 4-(4-Butylphenyl)-1-(2,5-dimethylanilino)phthalazine (69) 4-(4-Butylphenyl)-1 -(2,5-dimethoxyanilino)phthalazine (70) 4-(4-Butylphenyl)-1 -(3-chloroanilino)phthalazine(71) 4-(4-Butylphenyl)- 1 -(3-t?ifluornmethylanilino)phthalazine (72) 4-(4-Butylphenyl)-1 -(5-chloro-2-methoxyanilino)phthalazine (73) 1 -Anilino-4-(2,4-dimethylphenyl)phthalazine (74) 1 -Anilino-4-(4-methoxyphenyl)phthalazine (75) 1 -(4-Butylanilino)-4-(4-methoxyphenyl)phthalazine  t76) 1 -(2,5-Dimethylanilino)-4-(4-methoxyphenyl)phthalazine (77) 1-(2,5-Dimethoxyanilino)-4-(4-methoxyphenyl) phehalazine (78) 1-(3-Chloroanilino)-4-(4-methoxyphenyl)phthalazine (79)  4-(4-Methoxyphenyl)- 1 -(3-trifl uoromethylanilino)phthalazine (8) 1 -(5-Chloro-2-methoxyanilino)-4-(4-methoxyphenyl)phthalazine (81) 1 -(4-ethoxywarbonylanilino)-4-(4-methoxyphenyl)phthalazine (82) 1 -Anilino-4-(4-butoxyphenyl)phthalazine (83) 4-(4-Butoxyphenyl)-1 -(2,5-dimethylanilino)phthalazine (84) 4-(4-Butoxyphenyl)-1 -(2,5-dimethoxyanilino)phthalazine (85) 4-(4-Butoxyphenyl)-1 -(3-chloroanilino)phthalazine (86) 4-(4-Butoxyphenyl)-1-(3-trifluoromethylanilino)phthalazine (87) 4-(4-Butoxyphenyl)- 1 -(5-chloro-2-methoxyanilino)phthalazine(88) 1 -Anilino-4-(2,4-dimethoxyphenyl)phthalazine (89) 1 -(2,5-Dimethylanilino)-4-(2,4-dimethoxyphenyl)phthalazine (90)  1-(2,5-Dimethoxyanilino)-4-(2,4-dimethoxyphenyl)phthalazine(91) 1 -(3-Chloroanilino)-4-(2,4-dimethoxyphenyl)phthalazine (92) 4-(2,4-Dimethoxyphenyl)-1  -(3-trifluoromethylanilino)-phthalazine (93) 1 -(5-Chloro-2-methoxyanilino)-4-(2,4-dimethoxyphenyl)-phthalazine (94) 1 -Anilino-4-(4-chlorophenyl)phthalazine (95) 4-(4-Chlorophenyl)- 1 -(2,5-dimethylanilino)phthalazine (96) 4-(4-Chlorophenyl)- 1 -(2,5-dimethoxyanilino)phthalazine (97) 1-(3-Chloroanilino)-4-(4-chlorophenyl)-phthalazine (98) 4-(4-Chlorophenyl)- 1 -(3-trifluoromethylanilino)phthalazine (99) 1 -(5-Chloro-2-methoxyanilino)-4-(4-chlorophenyl)phthalazine (100) 1 -Anilino-4-(4-bromophenyl)phthalazine (101) 1 -Anilino-4-(4-fluorophenyl)phthalazine (102) 1  -(2,5-Dimethylanilino)-4-(4-fluorophenyl)phthalazine (103) 1 -(2,5-Dimethoxyanilino)-4-(4-fluorophenyi)phthalazine (104) 1 -(3-Chloroanilino)-4-(4-fluorophenyl)phthalazine (105) 4-(4-Fluorophenyl)- 1 -(3-trifl uoromethylani lino)phthalazine (106) 1 -(5-Chloro-2-methoxyanilino}-4-(4-fluorophenyl)phthalazine (107) 1 -Anilino-4-(4-ethoxycarbonylphenyl)phthalazine (108) 1 -(2,5-Dimethylanilino)-4-(4-ethoxycarbonylphenyl)phthalazine (109) 1 -(2,5-Dimethoxyanilino)-4-(4-ethoxycarbonylphenyl)phthalazine (110) 1 -(3-Chloroanilino)-4-(4-ethoxycarbonylphenyl)phthalazine (111) 4-(4-Ethoxycarbonylphenyl)-1 -(3-trifluoromethylanilino)phthalazine (112) 1 -(5-Chloro-2-methoxyanilino)-4-(4-ethoxycarbonylphenyl)phthalazine (113) 1 -Anilino-6-methyl-4-phenylphthalazine (114) 1-Anilino-7-methyl-4-phenylhthalazine (115) 1 -(2,5-Dimethylanilino)-6-methyl-4-phenylphthalazine (116) 1-(2,5-Dmethylanilino)-7-methyl-4-phenylphthalazine (117) 1-(2,5-Dimethylanilino)-6-methyl-4-phenylphthalazine (118) 1 -(2,5-Dimethoxyanilino)-7-methyl-4-phenylphthalazine (119) 1 -(3-Chloroanilino)-6-methyl-4-phenylphthalazine (120) 1 -(3-Chloroanilino)-7-methyl-4-phenylphthalazine (121) 6-Methyl-4-phenyl-1 -(3-trifluoromethylanilino)phthalazine (122) 7-Methyl-4-phenyl- 1 -(3-trifluoromethylanilino)phthalazine (123) 1 -(5-Chloro-2-methoxyanilino)-6-methyl-4-phenylphthalazine (124) 1 -(5-Chloro-2-methoxyanilino)-7-methyl-4-phenylphthalazine (125) 1-Anilino-6,7-dimethyl-4-phenylphthalazine (126)  1-(4-Butylanilino)-6,7-dimethyl-4-phenylphthalazine (127) 1-(2,5-Dimethylanilino)-6,7-dimethyl-4-phenylphthalazine (128) 1-(2,5-Dimethoxyanilino)-6,7-dimethyl-4-phenylphthalazine (129) - 1 -(4-Butoxyanilino)-6,7-dimethyl-4-phenylphthalazine (130) 1 -(3-Chloroanilino)-6,7-dimethyl-4-phenylphthalazine (131) 6,7-Dimethyl-4-phenyl-1 -(3-trifluoromethylanilino)phthalazine (132) 1 -(5-Chloro-2-methoxyanilino)-6,7-dimethyl-4-phenylphthalazine (133) 1 -(3-Chloro-4-methylanilino)-6,7-dimethyl-4-phenylphthalazine (134) 6,7-Dimethyl- 1 -(4-ethoxycarbonylanilino)-4-phenylphthalazine (135) 1 -Anilino-5,8-dimethyl-4-phenylphthalazine (136) 1 -(3-Chloroanilino)-5,8-dimethyl-4-phenylphthalazine (137) 1 -Anilino-6,7-dibutyl-4-phenylphthalazine (138) 1 -Anilino-6,7-dimethoxy-4-phenylphthalazine (139) 6,7-Dimethoxy- 1 -(2,5-dimethylanilino)-4-phenylphthalazine (140) 6,7-Dimethoxy- 1 -(2,5-dimethoxyanilino)-4-phenylphthalazine (141) 1-(3-Chloroanilino)-6,7-dimethoxy-4-phenylphthalazine (142) 6,7-Dimethoxy-4-phenyl-1 -(3-trifluoromethylanilino)phthalazine (143) 1 -(5-Chlorn-2-methoxyanilino)-6,7-dimethoxy-4-phenylphthalazine (144) 1 -(4-Butylanilino)-6,7-dimethoxy-4-phenylphthalazine (145) 1 -(4-Butoxyanilino)-6,7-dimethoxy-4-phenylphthalazine (146) 1 -Anilino-5,8-dimethoxy-4-phenylphthalazine (147) 1 -Anilino-6,7-dibutoxy-4-phenylphthalazine (148) 1 -Anilino-6,7-dichloro-4-phenylphthalazine (149) 6,7-Dichloro-1 -(2,5-dimethylanilino)-4-phenylphthalazine (150) 6,7-Dichloro-1-(2,5-dimethoxyanillno)-4-phenylphthalazine (151) 1 -(3-Chloroanilino)-6,7-dichloro-4-phenylphthalazine (152) 6,7-Dichloro-4-phenyl- 1 -(3-trifluoromethylanilino)phthalazine (153) 1 -(4-Chloro-2-methoxyanilino)-6,7-dichloro-4-phenylphthalazine (154) 1 -Anilino-5,8-dichloro-4-phenylphthalazine (155) 1 -Anilino-6-ethoxycarbonyl-4-phenylphthalazine (156) 1 -Anilino-6,7-dimethyl-4-(4-methylphenyl)phthalazine (157) 1 -(4-Butylanilino)-6,7-dimethyl-4-(4-methylphenyl)phthalazine (158) 6,7-Dimethyl-1 -(2,5-dimethylanilino)-4-(4-methylphenyl)phthalazine  (159) 6,7-Dimethyl- 1 -(3-methoxyanilino)-4-(4-methylphenyl)phthalazine (160) 1 -(2,5-Dimethoxyanilino)-6,7-dimethyl-4-(4-methylphenyl)-phthalazine (161) 1-(3-Chloroanilino)-6,7-dimethyl-4-(4-methylphenyl) phthalazine (162) 6,7-dimethyl-4-(methylphenyl)-1-(3-trifluoromethylanilino) phthanlazine (163) 1 -(4-Chloro-2-methoxyanilino)-6,7-dimethyl-4-(4-methylphenyl)phthalazine (164) 6,7-Dimethyl-1-(4-ethoxycarbonylanilino-4(4-methylphenyl) phthalaze (165) 1 -Anilino-4-(4-butylphenyl)-6,7-dimethylphthalazine (166) 1-Anilino-6,7-dimethyl-4-(4-methoxyphenyl0 phthalazine (167) 6,7-Dimethyl-1 -(2,5-dimethylanilino)-4-(4-methoxyphenyl)phthalazine (168) 1-(2,5-Dimethoxyanilino)-6,7-dimethyl-4-(4-methoxyphenyl) phthalazine (169) 1-(3-Chloroanilino)-6,7-dimethyl-4-(4-methoxyphenyl)phthalazine (170) 6,7-Dimethyl-4-(4-methoxyphenyl)-1 -(3-trifluoromethylanilino)phthalazine (171) 1 -(5-Chloro-2-methoxyanilino)-6,7-dimethyl-4-(4-methoxyphenyl)phthalazine (172) 1 -Anilino-4-(4-butoxyphenyl)-6,7-dimethylphthalazine (173) 1 -Anilino-4-(2,4-dimethoxyphenyl)-6,7-dimethylphthalazine (174) 1 -Anilino-4-(4-chlorophenyl)-6,7-dimethylphthalazine (175) 1-(3-Chloroanilino)-4-(4-chlorophenyl)-6,7-dimethylphthalazine (176) 1 -(3-Chloro-4-methylanilino)-4-(4-chlorophenyl)-6,7-dimethylphthalazine (177) 1-Anilino-6,7-dimethyl-4-(4-fluorophenyl)phthalazine (178) 1 -Anilino-6,7-dimethyl-4-(4-ethoxycarbonylphenyl)phthalazine (179) 1-Anilino-6,7-dimethoxy-5 (4-methylphenyl) phthalazine (180) 6,7-Dimethoxy- 1 -(2 ,5-dimethylanilino)-4-(4-methylphenyl)phthalazine (181) 6,7-Dimethoxy- 1  -(2,5-dimethoxyanilino)-4-(4-methylphenyl)phthalazine (182) 1 -(3-Chloroanilino)-6,7-dimethoxy-4-(4-methylphenyl)phthalazine (183) 1-Anilino-4-(4-butylphenyl)-6,7-dimethoxyphthalazine (184) 1 -Anilino-6,7-dimethoxy-4-(4-methoxyphenyl)phthalazine (185) 1 -Anilino-6,7-dimethoxy-4-(2,4-dimethoxyphenyl)phthalazine (186) 1 -Aniiino-4-(4-chlorophenyl)-6,7-dimethoxyphthalazine (187) 1-Aniiino-6,7-dimethoxy-4-(4-fluorophenyl)phthalazine (188) 1 -Anilino-6,7-dimethoxy-4-(4-ethoxycarbonylphenyl) phthalazine (189) 1 -Anilino-6,7-dichloro-4-(4-methylphenyl)phthalazine (190) 1-Anilino-4-(4-butylphenyl)-6,7-dichlorophthalazine (191) 1-Anilino-6,7-dichloro-4-(4-methoxyphenyl) phthalazine (192) 1 -Anilino-4-(4-butoxyphenyl)-6,7-dichlorophthalazine (193) 1 -Anilino-6,7-dichloro-4-(2,4-dimethoxyphenyl)phthalazine (194) 1 Anilino-4-(4-chlorophenyl)-6,7-dichlorophthalazine (195) 1 -Anilino-6,7-dichloro-4-(4-fluorophenyl)phthalazine (196) 1-Anilino-6,7-dichloro-4-(4-ethoxycarbonylphenyl)phthalazine (197) 1 -Anilino-4-(4-carboxyphenyl)phthalazine (198) 4-(4-Carboxyphenyl)- 1 -(2,5-dimethylanilino)phthalazine (199) 4-(4-Carboxyphenyl)- 1 -(2,5-dimethoxyanilino)phthalazine (200) 4-(4-Carboxyphenyl)- 1 -(3chloroanilino)phthalazine (201) 4-(4-Carboxyphenyl)- 1 -(3-trifl uoromethylanilino)phthalazine (202) 4-(4-Carboxyphenyl)- 1 -(5-chloro-2-methoxyanilino)phthalazine (203) 1-Anilino-4-(4-hydroxyphenyl) phthalazine (204) 1-(2,5-Dimethylanilino)-4-(4-hydroxyphenyl)phthalazine (205) 1-(2,5-Dimethylanilino)-4-(4-hydroxyphenyl)phthalazine (206) 1-(3-Chloroanilino)-4-(4-hydroxyphenyl)phthalazine (207) 4-(4-Hydroxyphenyl)-1 -(3-trifl uoromethylanilino)phthalazine (208) 1 -(5-Chlora-2-methoxyanilino)-4-(4-carboxyphenyl)phthalazine (209) 1-(4-Acetylanilino)-4-(4-methylphenyl)phthalazine (210) 1 -(4-Acetylanilino)-6,7-dimethyl-4-phenylphthalazine (211) 1 (4-Methylphenoxy)-4-phenylphthalazine (212) 1-(3-Methylphenoxy)-4-;;henylphthalazine (213) 1 -(2-Methylphenoxy)-4-phenylphthalazine (214) 1 -(4-Ethylphenoxy)-4-phenylphthalazine (215) 1 -(2-Ethylphenoxy)-4-phenylphthalazine (216) 1 -(4-n-Butylphenoxy)-4-phenylphthalazine (217) 1 -(3-Butylphenoxy)-4-phenylphthalazine (218) 1 -(4-t-Butylphenoxy)-4-phenylphthalazine (219) 1 -(4-Methoxyphenoxy)-4-phenylphthalazine (220) 1-(3-Methoxyphenoxy)-4-;;henylphthalazine (221) 1 -(3-Propoxyphenoxy)-4-phenylphthalazine (222) 1-(3-Butoxyphenoxy)-4-phenylphthalazine (223) 1 -(4-Fluorophenoxy)-4-phenylphthalazine  (224) 1-(3-Fluorophenoxy)-4-phenylphthalazine (225) 1 -(4-Chlorophenoxy)-4-phenylphthalazine (226) 1 (3-Chlorophenoxy)-4-phenylphthalazine (227) 1 -(2-Chlorophenoxy)-4-phenylphthalazine (228) 1 -(4-Bromophenoxy)-4-phenylphthalazine (229) 1 -(3-Bromophenoxy)-4-phenylphthalazine (230) 1-(3-lodophenoxy)-4-phenylphthalazine (231) 1 -(4-Ethoxycarbonylphenoxy)-4-phenylphthalazine (232) 1 -(4-Carboxyphenoxy)-4-phenylphthalazine (233) 1 -(4-Cyanophenoxy)-4-phenylphthalazine (234) 1-(4-Acetylphenoxy)-4-;;henylphthalazine (235) 1 -(4-Trifl uoromethylphenoxy)-4-phenylphthalazine (236) 1 -(3-Trifluoromethylphenoxy)-4-phenylphthalazine (237) 1 -(3-Hydroxyphenoxy)-4-phenylphthalazine (238) 1-(2,3-pimethylphenoxy)-4-phenylphthalazine (239) 1 -(2,5-Dimethylphenoxy)-4-phenylphthalazine (240) 1 -(2,5-Diethylphenoxy)-4-phenylphthalazine (241) 1 -(2,5-Dipropylphenoxy)-4-phenylphthalazine (242) 1 -(2,5-Dimethoxyphenoxy)-4-phenylphthalazine (243) 1 -(3,4-Dimethoxyphenoxy)-4-phenylphthalazine (244) 1 -(2,5-Dichlorophenoxy)-4-phenylphthalazine (245) 1-(2,6-Dichlorophenoxy)-4-phenylphthalazine (246) 1 -(2,5-Difluorophenoxy)-4-phenylphthalazine (247) 1 -(3-Chloro-4-methylphenoxy)-4-phenylphthalazine (248) 1 -(3-Methyl-4-chlorophenoxy)-4-phenylphthalazine (249) 1 -(3-Fluoro-4-methylphenoxy)-4-phenyl phthalazine (250) 1 -(2-Methoxy-4-chlorophenoxy)-4-phenylphthalazine (251) 1 -(2-Methoxy-5-methylphenoxy)-4-phenylphthalazinee (252) 1-(2-Methyl-4-trifluoromethylphenoxy)-4-phenylphthalazine (253) 1 -(2,4,6-Trimethylphenoxy)-4-phenylphthalazine Process for preparation of the compound (I) The compound represented by the formula [I] can be prepared according to any suitable process, which is not particularly limited.Preferably, however, the compound (I) can be synthesized by the following reaction route:
In the above formulae, X' represents -NH2 or OH; Y a halogen atom (e.g., chlorine, bromine oriodine), a group of the formula: S(0)pR4  (p=0--2, R4 is a C15 alkyl, phenyl or a substituted phenyl) or a group of the formula: -OR5 (R5 is a C15 alkyk, phenyl or a substituted phenyl); and all of the other symbols have the same meanings as defined above.
According to this process, the starting compound represented by the formula (II), namely 1 -chloro4-phenylphthalazine or its derivative, is allowed to react with a benzene derivative represented by the formula (III), in either the presence or absence of a solvent, preferably in the presence of a catalyst, to prepare a 4-phenylphthalazine derivative represented by the formula [I].
The starting materials, i.e., 1 -choloro-4-phenylphthalazine [II] or derivatives thereof were synthesized according to the method as described in Journal of Pharmacology 86, 576 (1966) or the methods similar thereto.
As the benzene derivative [III] to be reacted with the compound (II) as mentioned above, there may be employed suitable substituted anilines or substituted phenols.
 The reaction temperature may be in the range from -20 to 2500C., preferably from -10 to  1 800C. The reaction time may be from 5 minutes to 24 hours, preferably from 10 minutes to 10 hours.
When a catalyst is to be employed, there may be used an organic base such as ammonia, triethylamine, piperidine or pyridine, or an inorganic base such as sodium carbonate, potassium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride or sodium amide may be added at a molar ratio relative to the compound (II) in the range from 0.5 to 5, preferably from 1 to 3. Alternatively,it is also possible to use a metal such as copper, magnesium, cadmium, sodium or potassium, at a molarratio relative to the compound (II) in the range from 0.001 to 2, preferably from 0.01 to 1.5.
When a solvent is to be employed, there may be used a solvent selected from ethers such as ethylether, tetrahydrofuran, and dioxane; halogenated alkanes such as chloroform, methylene chloride, etc.; alcohols such as methanol, ethanol, etc.; aromatic hydrocarbons such as benzene, toluene, xyrene, etc.) amides such as defnethylformamide, dimethylacetamide, etc.; and dimethylsulfoxide; and so on.
The compound (Ill) may be used in an amount of 0.5 to 30 moles, preferably 1 to 2V moles, permole of the compound (II).
After completion of the reaction, the reaction mixture may be poured into a large excess of water or dissolved as such in a solvent such as chloroform to be neutralized therein. If desired, the precipitated orystals may be collected by filtration after concentration, or alternatively the product may be extracted with a suitable solvent such as chloroform when there is no precipitation, followed by recrystallization or chromatography according to conventional procedures.
The present invention is further illustrated by the following Examples, by which the present invention is not limited.
EXAMPLE 1Synthesis of I-(4-methylanilino)-4-phenylphthalazine (Compound No. Il To 2.41 g of 1 -chloro-4-phenylphthalazine, there were added 5.35 g of p-toluidine and 70 mg ofcopper powders. The mixture was then subjected to stirring under heating for one hour whilemaintaining the reaction temperature at 100 C. After the reaction mixture was left to cool, a largeexcess of chloroform was added thereto. The resultant insolubles were filtered off and the filtrate waswashed with a 5% aqueous sodium hydroxide and then with water. The organic layer was dried andconcentrated, and the residue was recrystallized from ethanol to give 910 mg (yield: 29%) of paleyellow crystals.
m.p.: 185-1860C.
 I.R.: cm-l, 1510 cm-l, 1410 cm-l M.S;: 310(M±1) EXAMPLES 2-30 The compounds as shown in Table 1 were synthesized according to the methods similar toExample 1.
TABLE 1
  Compound Example No. m.p./"C I  R/cm '  M.S.
 2 (2)  202@   203 3270, 1575, 1520 310  (M#1)    141D, 790  3 (3) 188 3200. 1500, 1400 311 (M+)  1200, 755 296  4 (4) 206  w  207 2990, 1625, 1520 324  (M - 1)    1420, 780  5 (6) 189  #   190 2860, 1620, 1520 353 (M+)  1420, 780 310  6 (9) 206  #   207.5 2950, 1640, 1510 327 (M+)  1420, 1240, 785 312  7 (10) 196 3000, 1610, 1500 326  (M#1 )     1400;  1155, 780  8 (12)  168.5 # 169   2950, 1620, 1505  369(M+)    1410, 1240, 790 312  9 (13) 206  # 207   3050, 1620, 1620 314  (M#1)   1410, 1220, 780  10 (14)  239 # 240   3280, 1620, 1520  314 (M#1)   1400, 1140, 790  11 (16) 193  # 194   1620, 1580, 1500 330  }  (M+)   1400, 820, 770 332  12 (17)  191 # 194   1600, 1510, 1420 330  1390, 770 332  13 (18) 170  # 171.5   3440, 1500, 1520  330 # (M+)   1400, 1040, 760 332  14 (19)  219 # 222   3000, 1625 1510 376  1400, 820, 780  374 (M#1)   15 (23)  236 # 237.5   3000, 1720, 1615 369  1520, 1410, 1280 368 (M+)  16 (25)  240 # 242.5   3360, 2210, 1610 321  (M#1)   1510, 1410, 790  17 (26)  247 #   248.5 3400, 1680, 1600 338  (M#1)    1520, 1400, 1280  18 (28)  174 # 175.5   3040, 1630, 1520  364 (M#1)    1410, 1340,  1100 TABLE 1 (Continued)
  Compound Example No. m.p./ C # R/cm M.S.
 19 (31)  240 # 242   3200, 1520, 1415 325 (M+)  790, 770 310  20 (32) 206.5  #   207.5  3400, 1500, 1400  325  (M+)  810, 780 310  21 (33)  202 # 203.5   3200, 1500, 1400 325 (M+)  810, 780 310  22 (34)  204 # 204.5   3200, 1510, 1420  324 (M#1)   790, 770  23 (37)  215 # 216   3440, 1610, 1520 357 (M+)  1430, 790 326  24 (43) 217 1590, 1510, 1410  347 # (M+)    780, 700  345    25 (44)  232 #   232.5 3400, 1490, 1400 347  820, 780, 700  346 # (M+)   26 (42) 171  #   172 3000, 1610, 1500 346  1400, 775, 700  344 # (M#1)   27 (47) 129  # 132   3450, 1530, 1430 341 (M+)  1230, 790, 710 310  28 (48)  74.575  1600, 1500, 1420 364  1220, 790, 780 362  #(M@@)    29 (51)  200 # 202.5    3200,1500,1400  339 (M+)  780, 700  30 (24) 250 < 3360, 1680, 1600 340 (M+1)  1520, 1410, 780 EXAMPLE 31Synthesis of 1 -(2-methylphenoxy)-4-phenylphthalazine (Compound No. 213)To 1.20 g of 1 -chloro-4-phenylphthalazine, there were added 5.40 9 of o-cresol and 360 mg of potassium hydroxide. The resultant mixture was subjected to stirring under heating for 2 hours, while maintaining the reaction temperature at 100 C.After the reaction mixture was poured into 12 ml of an aqueous solution having 3.6 g of potassium hydroxide dissolved therein, the crystals precipitated were recovered by filtration. The crude crystals were dissolved in chloroform, washed with water, dried and concentrated. Thea residue was recrystallized from ethanol-n-hexane to give 725 mg (yield : 46%) of white crystals.
136.5 - 137.5 CV.
1490 cm-1, 1385cm-1, 1230 cm-1,1190 cm-1, 790 cm-1, 750 cm-1.
M.S.: 312 (M+)EXAMPLES 32-44According to procedures similar to that as described in Example 31, there were synthesized the compounds as shown in Table 2.
TABLE 2
  Compound Example No. m.p./ C # R/cm M.S.
 32 (212)  148150.  1490, 1390, 1250 312 (M+)  1165, 800, 770 295  33 (214) 171.5  # 172 1510, 1385,  1210 326 (M+)  850, 770, 700 311  34 (218) 211  -212.5  2970, 1500, 1390 354 (M+)  1230, 790 339  35 (219) 163  ~164  1510,  i390,  1205 328 (M+)  1030, 850, 700 121  36 (227) 171  #  172 1550, 1480, 1380 331   +    1230, 790, 780 297  37 (228)  179 # 180   1490, 1380, 1220  3761(M+)    1010, 790 378  38 (234)  139 # 141.5   1700, 1600, 1380 340  1220, 850, 800  325 # (M+)   39 (236) 119  -  121 1450, 1385, 1330 366 (M+)  1170, 1120, 900 365  40 (28) 149  #   149.5 1596, 1380, 1220  332 # (M+)   890, 795, 700 334  41 (239) 153  -  155 @ 1570, 1385, 1250 326 (M+)   1120, 770 309  42 (248)  155.5156   1480,1390,  1240 346  I(M+)    1170, 1050, 790 348  43 (244) 175.5  #   176.5 1580, 1470, 1365 365  (M# 1)   1220, 1090, 770 331  44 (245)  210 # 210.5   1450, 1380, 1360 366 (M+)  1240, 770 331 EXAMPLE 45Synthesis of 1-(3-chloroanilino)-4-(4-methylphenyl) phthalazine (Compound No. 60) To 172 mg of 1 -chloro-4-(4-methylphenyl)phthalazine, there was added 319 mg of mchloroaniline, and the resultant mixture was heated at 1 000C with stirring for one hour. After the reaction mixture was left to cool to room temperature, a large excess of chloroform was added thereto, followed by washing with a 5% aqueous sodium hydroxide and then with water. The organic layer was dried and subjected to concentration. The residue was recrystallized from ethanol to give 145 mg (yield: 62%) of pale yellow crystals.
m.p. : 211.5 - 212. C.
 #.R. : 595 cm-1, 1510 cm-1, 1475 cm-1,1405 cm-1, 770 cm-1.
M.S.: 345 (M+), 343 (M+), 344.
EXAMPLES 46-109 The compounds as shown in Table 3, having the following formula:
were prepared according to the procedures similarly as described in Example 45. TABLE 3
 Compound Example No. R R R m.p./ C I.R./cm-1 MS 46 (63) 3-CF3 4-CH3 H 179-180 3240, 1595, 1510 379 (M+)  1400, 1330, 1160 378 47 (56) 2-CH2, 5-CH3 4-CH3 H 184-185 3200, 1610, 1490 339 (M+)  2-OCH3, 1405, 1020 324 48 (59) 5-OCH3 4-CH3 H 192.5-193 3425, 1800, 1510 371 (M+)  2-COH2 1420, 1200, 1035 340 49 (85) 4-Cl 4-CH3 H 197-197.5 3430, 1595, 1510 377 (M+)  1420, 1240, 1010 375 (M+) 50 (78) 3-Cl 4-OCH3 H 227-228 1600, 1460, 1400 363 (M+)  1250, 770 361 (M+)  360 51 (78) 3-CF3 4-OCH3 H 228-229 3230, 1610, 1515 396 (M+)  1405, 1335, 1250 394 52 (76) 2-CH3, 5-CH 4-OCH3 H 179-180 1610, 1490, 1400 355 (M+)  2-OCH3, 1250, 1175 340 53 (77) 5-OCH3 4-OCH3 H 185-186 3435, 1610, 1515 387 (M+)  1250, 1020 358 54 (80) 2-OCH2, 4-Cl 4-OCH3 H 206-207 3435, 1600, 1515 393 (M+)  1420, 1250, 1020 391 (M+) 55 (97) 3-Cl 4-Cl H 222-223 1600, 1480, 1410 367 (M+)  1080, 780 366 (M+)  364  TABLE 3 (Continued)
Example Compound R1 R2 R3 m.p./ C I.R./CM-1 MS  No.
56 (96) 3-CF3 4-Cl H 180-181 3270, 1605, 1450 401 (M+)  1415, 1340, 1120 399 (M+)  396 57 (95) 2-CH3, 5-CH 4-Cl H 196-197 1590, 1500, 1410 361 (M+)  1090, 935 369 (M+)  344 58 (96) 2-OCH3, 4-Cl H 190-192 3440, 1600, 1510 399 (M+)  5-OCH3 1430, 1220, 1045 391 (M+)  380 59 (99) 2-OCH3, 4-Cl H 200-201 3420, 1600, 1410 397 (M+)  4-Cl 1420, 1250 395 (M+)  384 60 (70) 3-Cl 4-C3H9 H 193-194 2920, 1600, 1410 389 (M+)  900, 770 387 (M+)  388 61 (71) 3-CF3 4-C4H9 H 164-167 2920, 1610, 1410 421 (M+)  1330, 1170, 1120 420 62 (88) 2-CH3 5-CH3 4-C4H9 H 169.5-171 2920, 1610, 1490 381 (M+)  1400, 805, 775 366 63 (89) 2-OCH3, 4-C4H9 H 169.5-160 2920, 1510, 1520 413 (M+)  5-OCH3 1430, 1205, 785 382 64 (72) 2-OCH3, 5-Cl 4-C4H9 H 173.6-174.5 3440, 2920, 1595 419 (M+)  1510, 1420, 1250 417 (M+)  398  TABLE 3 (Continued)
Example Compound R1 R2 R3 m.p./ C I.R./CM-1 MS  No.
65 (85) 3-Cl 4-OC4H9 H 184.5-185.5 2950, 1600, 1616 405 (M+)  1420, 1260, 770 403 (M+)  402 66 (86) 3-CF3 4-OC4H9 H 183-184 2950, 1610, 1510 437 (M+)  1400, 1330, 1110 436 67 (88) 2-CH3, 5-CH3 4-OC4H9 H 156.5-158 2950,1610, 1510 397 (M+)  1400, 1250 382 68 (84) 2-OCH3, 4-OC4H9 H 163-163.5 3440, 2950, 1605 429 (M+)  5-OCH3 1505,1240 398 69 (87) 2-OCH3, 4-OC4H9 H 181.5-182.5 3420, 2950, 1600 435 (M+)  5-Cl 1510, 1410, 1260 433 (M+)  402 70 (104) 3-Cl 4-F H 228.5-229.5 1600, 1515, 1420 351 (M+)  1220, 1150, 775 349  348 71 (105) 3-CF3 4-F H 205-206.5 1610, 1620, 1420 383 (M+)  1335, 1120, 800 382 72 (102) 2-CH3 4-F H 188.5-189.5 1600, 1500, 1415 343 (M+)  5-CH3 1225, 328 73 (103) 2-OCH3 4-F H 176-177 3445, 1600, 1510 375 (M+)  5-OCH3 1430, 1210, 1020 344 74 (105) 2-OCH3 4-F H 216-217 3445, 1600, 1515 381 (M+)  5-Cl 1430, 1240, 1015 379 (M+)  348  TABLE 3 (Continued)
Example Compound R1 R2 R3 m.p./ C I.R./CM-1 MS  No.
75 (91) 3-Cl 2-OCH3 H 200-201.5 1600, 1486 1400 393 (M+)  4-OCH3 1215, 1180, 775 391 (M+) 76 (92) 3-CF3, 2-OCH3 H 213-214 1620, 1500, 1400 425 (M+)  4-OCH3 1340, 1215, 1110 394 77 (89) 2-CH3 2-OCH3 H 220-221.5 1615, 1505, 1410 385 (M+)  5-CH3 4-OCH3 1215, 1160, 1040 370 78 (90) 2-OCH3 2-OCH3 H 177-177.5 3440, 1615, 1515 417 (M+)  5-OCH3 4-OCH3 1210, 1030 388 79 (93) 2-OCH3, 2-OCH3 H 203.5-205 3450, 1600, 1510 392 (M-1)  5-Cl 4-OCH3 1420, 1210, 1030 390 (M-1) 80 (110) 3-Cl 4-COOEt H 173-174 1710, 1590, 1500 405 (M+)  1410, 1270, 770 403 (M+)  402 81 (111) 3-CF3 4-COOEt H 215.5-216.5 1710, 1625, 1495 437 (M+)  1400, 1330, 1270 438 82 (108) 2-CH3, 4-COOEt H 201-5-202.5 3300, 1710, 1460 397 (M+)  5-CH3 1400, 1270, 1100 382 83 (109) 2-OCH3 4-COOEt H 198-199.5 3440, 1725, 1600 429 (M+)  5-OCH3 1560, 1270, 1090 398 84 (112) 2-OCH3, 4-COOEt H 208-207.5 3435, 1725, 1600 435 (M+)  5-Cl 1510, 1420, 1270 433 (M+)  402  TABLE 3 (Continued)
Example Compound R1 R2 R3 m.p./ C I.R./CM-1 MS  No.
85 (119) 3-Cl 6 -CH3 221-223 1590, 1475, 1400 347 (M+)  (120) H 7 -CH3 # mix. 1260, 770 345 (M+)  344 86 (121) 3-CF, 6 -CH3 221-222.5 1600, 1440, 1400 379 (M+)  (122) H 7 -CH3 # mix. 1330, 1150, 1110 378 87 (115) 2-CH3, 6 -CH3 164-168 1620, 1500, 1410 339 (M+)  (116) 5-CH3 H 7 -CH3 # mix. 800 324 88 (117) 2-OCH3, 6 -CH3 192-193 3430, 1600, 1520 371 (M+)  (118) 5-COH3 H 7 -CH3 # mix. 1450, 1210, 1210 340 89 (123) 2-OCH3, 6 -CH3 146-147.5 3430, 1600, 1510 377 (M+)  (124) 5-Cl H 7 -CH3 # mix. 1420, 1240, 1210 375 (M+)  344 90 (125) H H 6-CH3, 7-CH3 238-239 1605, 1500, 1410 326 (M+)  750 324 91 (130) 3-Cl H 6-CH3, 243.5-244.5 1606, 1500, 1400 361 (M+)  7-CH3 775, 765 359 (M+)  358 92 (131) 3-CF3 H 6-CH3, 255-258 1615, 1670, 1445 393 (M+)  7-CH3 1420, 1330, 1170 392 93 (127) 2-CH3, H 6-CH3, 153.5-156 1600, 1575, 1440 353 (M+)  5-CH3 7-CH3 810, 770 338 94 (128) 2-OCH3, H 6-CH3, 232-233 3450, 1610, 1520 385 (M+)  5-COH3 7-CH3 1400, 1220, 1010 354  TABLE 3 (Continued)
Example Compound R1 R2 R3 m.p./ C I.R./CM-1 MS  No.
95 (132) 2-OCH3, H 6-CH3, 237-238 3450, 1600, 1520 391 (M+)  5-Cl 7-CH3 1425, 1250, 1020 389 (M+)  358 96 (138) H H 6-OCH3, 205.5-207 1620, 1500, 1410 367 (M+)  7-COH3 1220, 1100, 750 358 97 (141) 3-Cl H 6-OCH3, 199.5-204 1620, 1600, 1520 393 (M+)  7-OCH3 1410, 1220, 775 391  390 98 (142) 3-CF3 H 6-OCH3, 223-228 1610, 1510, 1400 425 (M+)  7-OCH3 1330, 1155, 1115 424 99 (139) 2-CH3, H 6-OCH3, 192-193.5 1610. 1510, 1410, 385 (M+)  5-CH3 7-OCH3 1250, 1210 370 100 (140) 2-OCH3, H 6-OCH3, 158-158 3440, 1610, 1510 417 (M+)  5-OCH3, 7-OCH3 1410 1215, 1080 386 101 (143) 2-OCH3, H 6-OCH3, 211.5-213 3440, 1610, 1590 423 (M+)  5-Cl 7-OCH3 1510, 1410, 1240 421 (M+)  390 102 (144) 4-C4H5 H 6-OCH3, 167.5-189 2920, 1615, 1495 413 (M+)  7-OCH3 1405, 1240, 1090 412 103 (145) 4-OC4H5 H 6-OCH3, 183.5-186 2940, 1615, 1500 429 (M+)  7-OCH3 1405, 1220, 825 372 104 (151) 3-Cl H 6-OCH3, 248-250 1600, 1480, 1405 403 (M+)  7-OCH3 1090, 890, 760 402 (M+)  401 (M+)  400  TABLE 3 (Continued)
Example Compound R1 R2 R3 m.p./ C I.R./CM-1 MS  No.
105 (152) 3-CF, H 6-Cl, 243-244.5 1610, 1515, 1450 435 (M+)  7-Cl 1415, 1335, 1110 434 (M+)  433 (M+)  432 106 (149) 2-CH2, H 6-Cl, 204-205.5 1606, 1560, 1498 396 (M+)  5-CH, 7-Cl 1400, 1560, 393 (M+) 107 (150) 2-OCH3, H 6-Cl, 199.5-201 3435, 1610, 1560 427 (M+)  5-OCH3, 7-Cl 1400, 1210, 425 (M+)  394 108 (153) 2-OCH2, H 6-Cl, 201-202 3435, 1600, 1550, 431 (M+)  5-Cl 7-Cl 1500, 1420, 1250 429 (M+)  400 109 (202) 2-OCH3, 4-COOH H 274-275.5 3440, 1690, 1600, 405 (M+)  5-Cl 1510, 1420, 1240 374 Pharmacological tests:Artery blood of a rabbit was subjected to centrifugation to obtain platelet rich plasma. To an aliquot of 250 ,ul of the plasma, there was added 5 jul of each pharmaceutical solution. After incubation for two minutes, platelet aggregation was induced by adding 3 iug of collagen to the mixture. The change in platelet aggregationn was monitored and recorded by means of an aggregometer for 10 minutes.
The platelet aggregation inhibitory percentage was calculated by the following formula: Texts Inhibitory percentage= - x 100Tcwherein Tc is the degree of aggregation when only a solvent is added and Ts is that when apharmaceutical solution is added.
Table 4 shows inhibitory percentages at indicated mole concentrations for each compound. Asapparently seen from the results, among these compounds, the anilinophthalazine derivatives aregenerally found to have more potent activity than the phenoxyphthalazine derivatives.
TABLE 4
  Mole concentration  Compound Example No. 3 x  10''  10   1 (1) 56.5 33.9  2 (2) 80.6 66.1  3 (3) 100 60.9   4 (4) 100 100  5 (6) 100 100  6 (9) 76.6 39.1  7 (10)  100  100  8 (12) 100 100  9 -(13) 100 100  10 (14) 100 100  11 (16) 100 38.8  12 (17)  100  100  13 (18) 100 100  14- (19) 100 100  15 (23)  65.5  50.9   16 (25) 13.6  17 (26) 100 21.1  18 (28) 100 100  19 (31) 82.5 24.6  20 (32) 100 45.3   21 (33) 100 100  22 (34) 100 100  23 (37) 100 100  24 (43) 100 100  25 (44) 85.5 56.5  26 (42)  100  100  27 (47) 100 100  28 (48) 100 100  TABLE 4 (Continued)
  Mole concentration  Compound Example No.  3 x 10 6  10   29 (51) 100 100  30 (24)  13A -    31 (213) 100 100  32 (212) 100 51.3   33 (214) 100 30.4  34 (218)  6.38  9.6  35 (21 9) 100 100  36 (227) 73A 23.8   37 (228) 100 28.9  38 (234) 104  39 (236) 100 100  40 (226) 100 100  41 (239) 100 100  42 (248) 100 25.5  43 (244)  68A  26.3   44 (245)  84.1  15.9  45 (60) 100 100  46 (63) 100 100  47 (56) 100 7.6  48 (59) 100 100  49 (64) 100 100  50 (78) 100 100  51 (79) 100 100  52- (76) 33.6 11.8  53 (77) 100 100  54 (80) 100 100  55 (97) 100 100  56 (98) 100 100 TABLE 4 (Continued)
  Mole concentration  Compound Example No. 3 x 10-6  10'    57 (95) 58.7 15.1  58 (96) 100  59 (99) 100 100  60 (70) 28.0 23.4  61 (71) 100  26,2    62 (68) 55.8  63 (69) 100 100   64  (72) 100  54.9    65 (85) 30.5 18.3  66 (86) 482 25.9  67 (83) 27.9  68 (84) 100 100  69 (87) 61 2 35.8  70 (1 04) 100 66.7  71 (105) 100 74.1  72 (1 02) 100 69.8  73 (1 03) 100 91.9   74 (1 06) 84.4 50.0  75 (91) 92.6 10.6  76 (92) 29.7  77 (89) 100 84.9   78 (90) 30.5 11.9  79 (93) 17.7  80 (110) 12.0  81 (111) 48.2 36,6  82 (1 08) 30.5 4.3  83 (1 09) 100 100  84 (112) 100 100 TABLE 4 (Continued)
  Mole concentration  Compound Example No.  10-5  3 x10-6  1o-6    85  #(119)   100 100  (120)  86  #(121)   93.1 34.5  (122)  87  #(115)   100 100  (116)  88  #(117)   100 100  (118)  89  # (123)   100 100  90 (125) 100  91 (1 30) 100  92 (131) 100  93 (127) 100 23.1  94 (128) 100  95 (132) 100  96 (138) 9.1  97 (141) 10.7  98 (142) 46.3  103 (145) 8.9  104 (151) 13.3  105 (152) 100 152  107 (150) 15.8  108 (153) 27.6 SafetyEach of the compounds according to the present invention was found to be veryk low in toxicity, namely not less than 5000 mg/kg in terms of LD50 as measured by oral administration for mouse.